tricuspid aortic valves

EuroPCR 2024 | NOTION-2: TAVI vs SAVR, Randomized Study on Low-Risk Young Patients with Severe Tricuspid Disease or Bicuspid Stenosis

Many of the studies comparing TAVR against SAVR in low risk patients included patients between 70-75 years, excluding those with tricuspid valves.&nbsp; This study included low surgical risk patients with severe aortic stenosis and symptoms, 75 years or younger. Participants were randomized 1:1 to receiving TAVR or SAVR, stratified according to sex, need for new<a href="https://solaci.org/en/2024/05/17/europcr-2024-notion-2-tavi-vs-savr-randomized-study-on-low-risk-young-patients-with-severe-tricuspid-disease-or-bicuspid-stenosis/" title="Read more" >...</a>

¿Cómo objetivar la fragilidad en pacientes con estenosis aórtica?

Aortic Stenosis Progression Evolution

Aortic stenosis is an increasingly common valvulopathy because people are living longer now. A present, the main treatment consists of surgical (SAVR) or transcatheter aortic valve replacement. (TAVR). One of the main challenges of this disease is its progression. The European guidelines recommend Doppler echocardiograms every 2 to 3 years for mild cases, mildly calcified,<a href="https://solaci.org/en/2024/05/15/aortic-stenosis-progression-evolution/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

TAVR in Bicuspid Valves

Bicuspid aortic valve (BAV) disease affects 1%-2% of the population and manifests with severe aortic stenosis in the middle-aged.&nbsp; It characterizes for a very different anatomy with more calcification than the tricuspid aortic valve. At present, surgical aortic valve replacement (SAVR) is the first treatment indication.&nbsp; TAVR in this scenario has shown, in different studies,<a href="https://solaci.org/en/2024/05/07/tavr-in-bicuspid-valves/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Evolution of Bicuspid Valves at 12 Months

Severe aortic stenosis due to a bicuspid aortic valve (BAV) is uncommon, especially in individuals under 65 years of age. While there are usually no significant differences according to the type of valve when it comes to surgery, with transcatheter aortic valve replacement (TAVR) some may arise.&nbsp; TAVR has seen significant advancements in the treatment<a href="https://solaci.org/en/2024/01/12/evolution-of-bicuspid-valves-at-12-months/" title="Read more" >...</a>

El estudio CULPRIT-SHOCK finalmente se publica en el NEJM y llega para cambiar las guías

Aortic Stenosis and Cardiogenic Shock: Is TAVR an Option?

Cardiogenic shock (CS) in a setting of aortic stenosis is associated with high mortality rates. In consequence, surgery is generally not a possibility for this patient group, and they usually undergo aortic valvuloplasty, resulting in a mortality rate of 33%-50% at 30 days, 70% at one year, and 90% at two years. While transcatheter aortic<a href="https://solaci.org/en/2023/07/04/aortic-stenosis-and-cardiogenic-shock-is-tavr-an-option/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

New Devices for Percutaneous Treatment of Native Aortic Regurgitation: Expanding Horizons

Severe aortic regurgitation (AR) may account for 20% to 30% of all surgical aortic valve replacements (SAVR) and is often associated with aortic stenosis (AS). Transcatheter treatment of these patients is limited due to anatomical factors such as root and annular dilation, large annular dimensions, and less calcification in the valve leaflets to serve as<a href="https://solaci.org/en/2023/06/26/new-devices-for-percutaneous-treatment-of-native-aortic-regurgitation-expanding-horizons/" title="Read more" >...</a>

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

High Implantation of Self-Expanding Valves in the Aortic Position or Cusp Overlapping: Should It Be the New &#8220;Gold Standard&#8221;?

Transcatheter aortic valve replacement (TAVR) has been proving its benefit in different scenarios for two decades now. However, in the field of self-expanding valves, one challenge has always been its high rate of pacemaker implantation compared with balloon-expandable devices and valvular replacement surgery. For this reason, the high implantation or Cusp Overlapping strategy was developed.<a href="https://solaci.org/en/2023/04/20/high-implantation-of-self-expanding-valves-in-the-aortic-position-or-cusp-overlapping-should-it-be-the-new-gold-standard/" title="Read more" >...</a>

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation

Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis.&nbsp; This study included 45 patients with severe AR. Primary end<a href="https://solaci.org/en/2022/05/23/europcr-2022-jenavalve-trilogy-system-valve-for-severe-aortic-regurgitation/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Are Self-Expandable Valves a Valid Option in Bicuspids?

Bicuspid Aortic Valves (VAV) are challenging for TAVR given its anatomical characteristics and the important presence of calcification. However, current data are promising.&nbsp; Even though traditionally excluded from the larger randomized studies, self-expandable valves appear to have similar evolution to tricuspid aortic valves (TAV) with severe stenosis.&nbsp; Researchers looked at the Low-Risk Bicuspid Study and<a href="https://solaci.org/en/2022/03/16/are-self-expandable-valves-a-valid-option-in-bicuspids/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

Are Expandable-Balloon Valves an Option for the Bicuspid Valve in Low-Risk Patients?

Bicuspid aortic valve malformation is the most frequent cardiac malformation (about 1%), and a significant percentage of these cases generate severe aortic stenosis. As we know, transcatheter aortic valve replacement (TAVR) has been developed for tricuspid valves, which are studied in the most important randomized trials for high-, medium-, and low-risk patients. While current information<a href="https://solaci.org/en/2022/03/16/are-expandable-balloon-valves-an-option-for-the-bicuspid-valve-in-low-risk-patients/" title="Read more" >...</a>

Top